Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...